Research programme: heat shock protein 90 inhibitors - ArQuleAlternative Names: ARQ-250RP; Hsp90-inhibitors
Latest Information Update: 11 Apr 2011
At a glance
- Originator ArQule
- Class Small molecules
- Mechanism of Action HSP90 heat-shock protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 07 Jul 2006 Preclinical trials in Cancer in USA (unspecified route)